Intrinsiqq
Replimune Group Inc. logo

Replimune Group Inc. Insider Trading

REPL

Compare
Last 12 months

Insiders sold $4.11M and bought nothing on the open market.

7% of the selling was scheduled in advance under 10b5-1 plans. Chief Executive Officer Sushil Patel sold $1.06M on Nov 16, 6.9% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2019.

Net open-market
−$4.11M
0 buys · 21 sales
Under a 10b5-1 plan
7%
of the value sold
Insiders who bought / sold
0 / 8
executives and directors
Last open-market buy
Nov 2019
Nov 18, 2019

Get an email when REPL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 16No plan
    Konstantinos Xynos
    Chief Medical Officer · sold 16,198 at $21.60
    350K
    7.2% of stake
  • Nov 16No plan
    Andrew Schwendenman
    Chief Accounting Officer · sold 2,148 at $21.60
    46K
    2.2% of stake
  • Nov 16No plan
    Sushil Patel
    Chief Executive Officer · sold 49,026 at $21.60
    $1.06M
    6.9% of stake
  • Nov 16No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 14,709 at $21.60
    318K
    6.8% of stake
  • Nov 9No plan
    Joseph P Slattery
    Director · sold 5,200 at $21.80
    113K
    78% of stake
  • Nov 2No plan
    Kapil Dhingra
    Director · sold 21,500 at $19.00
    409K
    50% of stake
  • Aug 17No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 9,256 at $14.28
    132K
    4.1% of stake
  • Aug 10No plan
    Sushil Patel
    Chief Executive Officer · sold 39,341 at $12.97
    510K
    5.3% of stake
  • Aug 10No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 11,448 at $12.97
    148K
    4.8% of stake
  • Aug 10No plan
    Konstantinos Xynos
    Chief Medical Officer · sold 11,447 at $12.97
    148K
    4.9% of stake
  • Aug 10No plan
    Andrew Schwendenman
    Chief Accounting Officer · sold 7,632 at $12.97
    99K
    7.1% of stake
  • Jun 110b5-1 plan
    Christopher Sarchi
    Chief Commercial Officer · sold 12,000 at $9.24
    111K
    6.2% of stake
  • May 18No plan
    Konstantinos Xynos
    Chief Medical Officer · sold 14,023 at $5.08
    71K
    5.6% of stake
  • May 18No plan
    Andrew Schwendenman
    Chief Accounting Officer · sold 7,894 at $5.08
    40K
    6.9% of stake
  • May 18No plan
    Christopher Sarchi
    Chief Commercial Officer · sold 8,626 at $5.08
    44K
    4.3% of stake
  • May 18No plan
    Philip Astley-Sparke
    Director · sold 17,657 at $5.08
    90K
    1.2% of stake
  • May 18No plan
    Sushil Patel
    Chief Executive Officer · sold 37,324 at $5.08
    190K
    4.8% of stake
  • May 18No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 7,812 at $5.08
    40K
    3.2% of stake
  • Apr 210b5-1 plan
    Christopher Sarchi
    Chief Commercial Officer · sold 6,500 at $8.01
    52K
    4.1% of stake
  • Dec 9, 2025No plan
    Kapil Dhingra
    Director · sold 3,169 at $10.40
    33K
    100% of stake
  • Dec 2, 202510b5-1 plan
    Sushil Patel
    Chief Executive Officer · sold 10,000 at $11.13
    111K
    2.9% of stake
  • Nov 17, 2025No plan
    Christopher Sarchi
    Chief Commercial Officer · sold 5,208 at $9.10
    47K
    4.1% of stake
  • Nov 17, 2025No plan
    Konstantinos Xynos
    Chief Medical Officer · sold 7,248 at $9.10
    66K
    4.9% of stake
  • Aug 15, 2025No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 9,154 at $5.37
    49K
    6.4% of stake
  • May 20, 2025No plan
    Philip Astley-Sparke
    Director · sold 32,279 at $8.06
    260K
    2.2% of stake
  • May 20, 2025No plan
    Konstantinos Xynos
    Chief Medical Officer · sold 7,952 at $8.06
    64K
    5.1% of stake
  • May 20, 2025No plan
    Andrew Schwendenman
    Chief Accounting Officer · sold 3,287 at $8.05
    26K
    4.6% of stake
  • May 20, 2025No plan
    Sushil Patel
    Chief Executive Officer · sold 25,105 at $8.06
    202K
    6.8% of stake
  • May 20, 2025No plan
    Emily Luisa Hill
    Chief Financial Officer · sold 2,535 at $8.05
    20K
    1.7% of stake
  • May 20, 2025No plan
    Christopher Sarchi
    Chief Commercial Officer · sold 3,749 at $8.05
    30K
    2.8% of stake
  • Dec 16, 202410b5-1 plan
    Sushil Patel
    Chief Executive Officer · sold 10,000 at $12.42
    124K
    4.7% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch REPL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with REPL

CompareIntrinsic value
ARTVArtiva Biotherapeutics Inc.
$3.78-1.31%10
SRZNSurrozen, Inc.
$28.46-7.21%10
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
DNAGinkgo Bioworks Holdings Inc.
$7.46-9.02%15
IMAImageneBio, Inc.
$3.92-1.51%10
EDITEditas Medicine Inc.
$1.64-4.09%40
CMPXCompass Therapeutics Inc.
$0.69+1.40%10
IBRXImmunityBio, Inc.
$6.02-8.37%30

Held by ETFs

REPL is in 26 US ETFs. The largest of them, with REPL's weight in each:

Spot a number that looks wrong? Check it in REPL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing REPL

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.